ImmuPharma PLC
LSE:IMM
ImmuPharma PLC
LSE:IMM
Price:
6.64
GBX
-1.48%
Market Closed
Market Cap:
£33.4m
Relative Value
The Relative Value of one
IMM
stock under the Base Case scenario is
0.02
GBX.
Compared to the current market price of 6.64 GBX,
ImmuPharma PLC
is
Overvalued by 100%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IMM
Relative Value
Base Case
0.02
GBX
Overvaluation 100%
Multiples Across Competitors
IMM Competitors Multiples
ImmuPharma PLC Competitors
ImmuPharma PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
ImmuPharma PLC
LSE:IMM
|
33.2m GBP | 0 | -8.4 | -12.3 | -12 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
930.7B USD | 14.3 | 45.1 | 30.4 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581.6B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.7B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.2B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.1B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD | 2.4 | 19.4 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
